<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnosis, treatment, and prevention of adenovirus infection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnosis, treatment, and prevention of adenovirus infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnosis, treatment, and prevention of adenovirus infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Flor M Munoz, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Phyllis Flomenberg, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 11, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Adenoviruses are a family of deoxyribonucleic acid (DNA) viruses that are an important cause of febrile illnesses in young children. They are most frequently associated with upper respiratory tract syndromes such as pharyngitis or coryza but can also cause pneumonia. Less commonly, adenoviruses cause gastrointestinal, ophthalmologic, genitourinary, neurologic, and disseminated disease. Most adenoviral diseases are self-limiting, although fatal infections can occur in immunocompromised hosts and occasionally in healthy children and adults.</p><p>The available diagnostic tests and strategies for treatment and prevention of adenovirus infection will be reviewed here. The virology, epidemiology, and clinical manifestations of adenovirus infection are discussed separately. (See  <a class="medical medical_review" href="/d/html/8339.html" rel="external">"Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection"</a>.)</p><p class="headingAnchor" id="H18818874"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Since adenoviruses are associated with a variety of clinical syndromes and nonspecific manifestations, diagnosis based upon clinical criteria alone is challenging. The diagnosis of adenovirus disease should be confirmed in outbreaks of infection and in individual patients with serious disease manifestations. Confirmation of adenovirus infection is important in order to decide on the use of antiviral agents, exclude other treatable infections, establish a prognosis, and initiate infection control measures when appropriate.</p><p class="headingAnchor" id="H2"><span class="h1">DIAGNOSTIC TESTS</span><span class="headingEndMark"> — </span>A number of different approaches are available for the specific diagnosis of adenovirus infection (<a class="graphic graphic_table graphicRef59727" href="/d/graphic/59727.html" rel="external">table 1</a>). Viral culture, adenovirus-specific viral antigen assays, and polymerase chain reaction (PCR) assays are used most frequently.</p><p class="headingAnchor" id="H3"><span class="h2">Viral culture</span><span class="headingEndMark"> — </span>All adenovirus serotypes except types 40 and 41 cause a characteristic cytopathic effect (CPE) in human epithelial cell lines such as HeLa, A549, or HEp2 and in primary human embryonic kidney cells. CPE generally occurs within 2 to 7 days with the common lower serotypes, but some others, especially subgroup D serotypes (which cause epidemic keratoconjunctivitis [EKC]), can require up to 28 days.</p><p>Adenoviruses are relatively stable and can be readily recovered from clinical samples early in the course of the disease. Appropriate samples include nasopharyngeal swabs or aspirates, throat swabs or washes, sputum, tracheal aspirates, bronchoalveolar lavage (BAL) fluid, conjunctival swabs or scrapings, stool or rectal swabs, urine, blood, cerebrospinal fluid (CSF), and tissue samples. Swabs and tissue biopsies should be placed in a viral transport medium to prevent drying and to inhibit bacterial overgrowth. Specimens should be transported to the laboratory on ice. The duration of viral excretion at the time of acute disease is approximately one to three days from throat in adults with upper respiratory infection; three to five days from nose, throat, and eye in patients with pharyngoconjunctival fever; and two weeks from eye cultures in patients with keratoconjunctivitis. Viral excretion may be prolonged (for weeks) in young children [<a href="#rid1">1-4</a>].</p><p>After acute infection, adenoviruses may be intermittently excreted in stool (or upper respiratory tract, less commonly) for months in some patients. In immunocompromised hosts, adenoviruses may be continuously shed from stool or urine for months without symptoms. Therefore, a positive culture result needs to be interpreted based upon the current clinical manifestations. (See  <a class="medical medical_review" href="/d/html/8339.html" rel="external">"Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Viral antigen assay</span><span class="headingEndMark"> — </span>Direct detection of adenovirus antigens in clinical samples may be performed by an adenovirus-specific enzyme immunoassay (EIA) or immunofluorescence assay. These assays are more rapid but less sensitive than viral culture for the detection of most serotypes [<a href="#rid5">5</a>]. They are insufficiently sensitive for diagnosis in immunocompromised hosts [<a href="#rid6">6</a>].</p><p>Commercially available assays use adenovirus-specific monoclonal antibodies that react with common antigenic determinants on all serotypes. In particular, antigen assays are the test of choice for the detection of the fastidious adenovirus types 40 and 41 in stool samples [<a href="#rid7">7</a>]. These enteric adenoviruses are an important cause of diarrhea in infants.</p><p>Another application for direct antigen assays is in the rapid diagnosis of EKC. (See <a class="local">'Epidemic keratoconjunctivitis'</a> below.)</p><p>Direct adenovirus antigen assays can also be used to screen cell cultures before the development of CPE, as well as to confirm the presence of adenovirus in cell cultures positive for CPE.</p><p class="headingAnchor" id="H7"><span class="h2">Polymerase chain reactions</span><span class="headingEndMark"> — </span>PCR is a highly sensitive and specific assay that can be used to detect adenovirus DNA from a variety of clinical specimens including fixed tissues. PCR is particularly helpful in samples from normally sterile sites such as blood, CSF, and tissues. A positive result from upper respiratory tract or stool samples is more difficult to interpret as it may represent virus shedding rather than symptomatic infection. Therefore, PCR results must be interpreted in the context of the clinical findings of adenovirus disease. Because different adenovirus serotypes are heterogeneous at the DNA level, PCR primers may be selected to detect specific serotypes or related serotypes [<a href="#rid8">8</a>]. Commercial adenovirus PCR assays use universal primers and probes that detect most or all serotypes [<a href="#rid9">9,10</a>].</p><p>Detection of adenovirus DNA in the blood by quantitative PCR is increasingly utilized for the evaluation of adenovirus infections in immunocompromised patients [<a href="#rid9">9,11</a>]. Studies have demonstrated an association between rising or high-level viremia and the risk of both invasive disease and mortality [<a href="#rid12">12,13</a>]. In addition, quantification of adenovirus DNA can be used to assess response to antiviral treatment [<a href="#rid14">14-17</a>]. In one study, a greater than 10-fold decrease in viral load one week after the first dose of antiviral therapy was associated with a favorable clinical course, whereas all patients with fatal disease failed to show a significant reduction in viral load [<a href="#rid14">14</a>]. PCR can also be used in conjunction with sequencing in order to rapidly genotype adenovirus isolates [<a href="#rid18">18</a>]. (See <a class="local">'Serotyping and genotyping'</a> below.)</p><p>PCR has been used to diagnose adenovirus myocarditis. Routine viral cultures and histopathology are rarely positive in cases of presumed viral myocarditis. In one study, 38 myocardial tissue samples from 34 patients with acute myocarditis and 17 control patients with congenital heart disease or hypertrophic cardiomyopathy were tested by PCR for adenovirus and enterovirus [<a href="#rid19">19</a>]. Although enteroviruses have been implicated as the major etiology of viral myocarditis, adenovirus DNA was detected more commonly (15 samples) than enterovirus DNA (8 samples). All control samples were negative. In another report, PCR was used to make a diagnosis of intrauterine adenovirus myocarditis [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/4933.html" rel="external">"Myocarditis: Causes and pathogenesis", section on 'Adenovirus'</a> and  <a class="medical medical_review" href="/d/html/4939.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in adults", section on 'Identifying the cause of myocarditis'</a> and  <a class="medical medical_review" href="/d/html/5755.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in children", section on 'Endomyocardial biopsy'</a>.)</p><p>In addition, detection of adenovirus by PCR in heart biopsies of cardiac transplant recipients may correlate with increased graft loss [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Histopathologic studies</span><span class="headingEndMark"> — </span>Definitive diagnosis of adenovirus disease may require tissue biopsy. Specimens should be obtained for both pathology and viral culture or PCR because routine histopathology may be nonspecific, especially in the early stages of infections.</p><p>Adenoviruses can cause characteristic intranuclear inclusions (<a class="graphic graphic_picture graphicRef56007" href="/d/graphic/56007.html" rel="external">picture 1</a>) [<a href="#rid22">22</a>]. Early post-infection, cells may display small eosinophilic inclusions. During the later stages of infection, basophilic inclusions appear, which initially may be surrounded by a clear halo within the nucleus. When these intranuclear inclusions enlarge and obscure the nuclear membrane, the cells are referred to as "smudge" cells (<a class="graphic graphic_picture graphicRef56007" href="/d/graphic/56007.html" rel="external">picture 1</a>). Occasionally, adenovirus inclusions may be confused with cytomegalovirus (CMV) inclusions, but, unlike CMV, adenoviruses cause neither intracytoplasmic inclusions nor multinucleated cells [<a href="#rid23">23</a>].</p><p>If routine histopathology is non-diagnostic and viral culture of tissue is negative (or not done), more specialized tests may be performed on tissue samples. Electron microscopy can be used to detect the characteristic icosahedral virions that typically form large paracrystalline aggregates with the nuclei of infected cells [<a href="#rid24">24</a>]. Adenovirus-specific immunohistochemical assays and in situ DNA assays are also available [<a href="#rid25">25,26</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Serology</span><span class="headingEndMark"> — </span>Recent infection may be documented by assay of paired acute and convalescent sera for adenovirus-specific antibodies [<a href="#rid27">27</a>]. It is important to document a fourfold or greater rise in antibody titer because there is a high prevalence of anti-adenovirus antibodies in the general population, and there are numerous cross-reactions between related serotypes.</p><p>Commercially available EIAs and complement fixation assays measure adenovirus-specific anti-hexon antibodies but do not provide information about the serotype. In contrast, detection of hemagglutination inhibition antibodies or neutralizing antibodies is more sensitive and is serotype specific. These assays are primarily performed in reference laboratories and are best interpreted when the patient's sera is tested against the patient's own isolate.</p><p class="headingAnchor" id="H18818704"><span class="h2">Serotyping and genotyping</span><span class="headingEndMark"> — </span>After recovery of a clinical isolate on tissue culture, further evaluation can be performed by serotype analysis in a reference virology laboratory. Certain serotypes are associated with distinct clinical manifestations (<a class="graphic graphic_table graphicRef63104" href="/d/graphic/63104.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/8339.html" rel="external">"Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection"</a>.)</p><p>The serotype is determined by first grouping the isolate by hemagglutination pattern with rat and rhesus red blood cells. Then, hemagglutination inhibition and/or serum neutralization assays can be performed using a selected panel of type-specific sera. Genotyping can also be accomplished by PCR and sequencing, which is substantially faster than the traditional serotyping methods, although it is not widely available. (See <a class="local">'Polymerase chain reactions'</a> above.)</p><p class="headingAnchor" id="H18818726"><span class="h2">Restriction endonuclease analysis</span><span class="headingEndMark"> — </span>Restriction endonuclease (RE) analysis can distinguish between different clinical isolates of the same serotype. RE analysis is useful for epidemiologic analysis (eg, during outbreaks of adenovirus infection). As an example, RE was used to analyze isolates obtained during an outbreak of EKC caused by adenovirus serotype 8 [<a href="#rid28">28</a>]. In this epidemic, cases occurred simultaneously in two childcare centers, followed by prolonged outbreaks within the community and among staff at the local hospital. RE analysis of the genomes of five isolates revealed they were identical and distinct from the prototype adenovirus serotype 8, supporting the conclusion that the cases in the larger outbreak were connected.</p><p class="headingAnchor" id="H10"><span class="h1">DIAGNOSTIC TESTS OF CHOICE FOR DIFFERENT ADENOVIRUS SYNDROMES</span><span class="headingEndMark"> — </span>The diagnostic test of choice varies depending upon the clinical scenario (<a class="graphic graphic_table graphicRef81573" href="/d/graphic/81573.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H11"><span class="h2">Upper respiratory illness</span><span class="headingEndMark"> — </span>Adenoviruses should be suspected as one of the causes of febrile illnesses with respiratory symptoms in infants and young children. Adenoviruses are a common cause of tonsillitis in young children. Conjunctivitis accompanied by pharyngeal symptoms, known as pharyngoconjunctival fever, is a characteristic, though less frequent, adenovirus syndrome. Adenoviruses are also implicated in outbreaks of febrile respiratory disease in summer camps and swimming pools. (See  <a class="medical medical_review" href="/d/html/8339.html" rel="external">"Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection", section on 'Respiratory tract'</a>.)</p><p>When warranted, such as during an epidemic, diagnosis can be confirmed by viral culture of the nasopharynx or throat. If viral culture is unavailable, the specimen may be tested with the less sensitive adenovirus-specific enzyme-linked immunosorbent assay (ELISA).</p><p>The differential diagnosis includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Rhinovirus (see  <a class="medical medical_review" href="/d/html/8335.html" rel="external">"Epidemiology, clinical manifestations, and pathogenesis of rhinovirus infections"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Influenza (see  <a class="medical medical_review" href="/d/html/5973.html" rel="external">"Seasonal influenza in children: Clinical features and diagnosis", section on 'Whom to test'</a> and  <a class="medical medical_review" href="/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory syncytial virus (see  <a class="medical medical_review" href="/d/html/5994.html" rel="external">"Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children", section on 'Laboratory confirmation'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parainfluenza (see  <a class="medical medical_review" href="/d/html/5975.html" rel="external">"Parainfluenza viruses in children", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/7009.html" rel="external">"Parainfluenza viruses in adults", section on 'Diagnosis'</a>)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Epidemic keratoconjunctivitis</span><span class="headingEndMark"> — </span>Adenoviruses are the most common cause of epidemic keratoconjunctivitis (EKC), a syndrome characterized by eye pain and inflammation, fever, and preauricular lymphadenopathy. EKC is highly contagious and often occurs in outbreaks.</p><p>It is best to obtain conjunctival swabs for both viral culture and adenovirus-specific ELISA or polymerase chain reaction (PCR) assay to make a diagnosis of EKC, since subgroup D isolates, which are frequently implicated, can take two to four weeks to grow in tissue culture.</p><p>A rapid (10-minute) point-of-care immunoassay for adenoviral conjunctivitis is commercially available [<a href="#rid29">29</a>]. In a prospective multicenter study, it had a sensitivity of 90 percent and specificity of 96 percent compared with viral culture and a sensitivity of 85 percent and specificity of 98 percent when compared with PCR [<a href="#rid30">30</a>]. In a subsequent study in the emergency department setting, sensitivity was 39.5 percent and specificity was 95.5 percent compared with PCR [<a href="#rid31">31</a>]. Given the broad range for sensitivity, negative results do not exclude adenovirus conjunctivitis.</p><p>The differential diagnosis includes bacterial conjunctivitis as well as other viral pathogens such as enteroviruses and herpes simplex virus. (See  <a class="medical medical_review" href="/d/html/6907.html" rel="external">"Conjunctivitis", section on 'Bacterial conjunctivitis'</a> and  <a class="medical medical_review" href="/d/html/2693.html" rel="external">"Enterovirus and parechovirus infections: Clinical features, laboratory diagnosis, treatment, and prevention", section on 'Ocular infections'</a> and  <a class="medical medical_review" href="/d/html/8334.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection", section on 'Keratitis'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Pneumonia</span><span class="headingEndMark"> — </span>Adenoviruses are an important etiology of fever and interstitial pulmonary infiltrates in infants and children. Although uncommon in adults, there have been well-described outbreaks of adenovirus pneumonia among military recruits and among adults in chronic care facilities [<a href="#rid32">32,33</a>]. A diagnosis can be made by viral culture, direct antigen assay, or PCR assay on a nasopharyngeal aspirate or swab, throat swab, sputum sample, or bronchoalveolar lavage fluid.</p><p>Multiplex PCR assays that detect a panel of respiratory viruses including adenovirus from nasopharyngeal specimens are especially useful for evaluation of hospitalized patients with suspected respiratory viral pneumonia or other influenza-like illness [<a href="#rid34">34,35</a>]. However, in a prospective study that compared the prevalence of viruses in the upper respiratory tracts of children and adults with community-acquired pneumonia with the prevalence in asymptomatic controls, detection of adenovirus was associated with pneumonia only in children &lt;2 years of age [<a href="#rid36">36</a>]. This suggests that adenovirus may not be the causative pathogen of pneumonia in all patients in whom it is detected (especially in those ≥2 years of age).</p><p>The differential diagnosis includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory syncytial virus (see  <a class="medical medical_review" href="/d/html/5994.html" rel="external">"Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children", section on 'Laboratory confirmation'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Influenza (see  <a class="medical medical_review" href="/d/html/5973.html" rel="external">"Seasonal influenza in children: Clinical features and diagnosis", section on 'Whom to test'</a> and  <a class="medical medical_review" href="/d/html/7004.html" rel="external">"Seasonal influenza in adults: Clinical manifestations and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parainfluenza (see  <a class="medical medical_review" href="/d/html/7009.html" rel="external">"Parainfluenza viruses in adults", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/5975.html" rel="external">"Parainfluenza viruses in children", section on 'Diagnosis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human metapneumovirus (see  <a class="medical medical_review" href="/d/html/8311.html" rel="external">"Human metapneumovirus infections", section on 'Clinical manifestations'</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Diarrhea in young children</span><span class="headingEndMark"> — </span>Although norovirus is the more common pathogen, enteric adenoviruses (types 40 or 41) can cause a prolonged diarrheal syndrome in infants, especially in the setting of clusters (eg, in daycare centers or as a healthcare-associated infection). The test of choice is an adenovirus-specific PCR or ELISA on a stool specimen because enteric adenoviruses do not grow on routine tissue culture. Symptoms are self-limited and treatment is supportive. Strict infection control methods in daycare centers may help to prevent transmission.</p><p class="headingAnchor" id="H1160112234"><span class="h2">Hepatitis</span><span class="headingEndMark"> — </span>Beginning in October 2021, adenovirus has been associated with clusters of unexplained severe hepatitis in previously healthy children in the United Kingdom, the United States, and multiple other countries, but causality has not been confirmed. During the outbreak, the United States Centers for Disease Control and Prevention provides guidance <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fncird%2Finvestigation%2Fhepatitis-unknown-cause%2Fhcp.html&amp;token=wudcwwI609uIujZyg0qaaA9Zuj76eFCyjoz4rs6qoWB7a8DAuQTGs8W%2FUzJ8NFuJGkKjREXAW8YSt7zsNrCOLSt5toaZnCVZ4O7cKhOo9Fk%3D&amp;TOPIC_ID=8348" target="_blank">for adenovirus testing and typing</a> in children being evaluated for acute hepatitis of unknown etiology. (See  <a class="medical medical_review" href="/d/html/16142.html" rel="external">"Acute liver failure in children: Etiology and evaluation", section on 'Outbreak 2022'</a> and  <a class="medical medical_review" href="/d/html/8339.html" rel="external">"Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection", section on 'Acute hepatitis'</a>.)</p><p>The evaluation for adenovirus hepatitis in immunocompromised hosts is discussed below. </p><p class="headingAnchor" id="H15"><span class="h2">Infections in immunocompromised hosts</span><span class="headingEndMark"> — </span>Adenoviruses cause a wide range of clinical syndromes in immunocompromised hosts, including pneumonia, hemorrhagic cystitis, nephritis, colitis, hepatitis, encephalitis, and disseminated disease. Adenovirus infections commonly occur in immunocompromised children resulting from either reactivation of latent infection or primary infection. Because adenoviruses may be shed asymptomatically in throat, stool, or urine, it is often necessary to obtain tissue to diagnose some types of disease. (See  <a class="medical medical_review" href="/d/html/8339.html" rel="external">"Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection", section on 'Infections in immunocompromised hosts'</a>.)</p><p>Adenoviruses may cause severe, sometimes fatal, disease in hematopoietic stem cell transplant recipients. After hematopoietic stem cell transplantation, recovery of T cell function and adenovirus-specific T cells has been associated with a favorable outcome [<a href="#rid37">37,38</a>]. Recipients of T cell-depleted grafts or those with graft-versus-host disease are at highest risk for disease and mortality. (See  <a class="medical medical_review" href="/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation"</a>.)</p><p>The specific diagnosis of adenovirus infection in immunocompromised patients may require the use of multiple diagnostic modalities on various specimens. PCR, viral culture, or direct antigen assays of upper nasopharyngeal, throat, urine, and stool or rectal samples will detect viral shedding. Results should be interpreted in the context of clinical manifestations consistent with adenovirus infection. In addition, testing of blood and affected sites (including lower respiratory tract secretions collected by tracheal aspirate or bronchoalveolar lavage in patients with pneumonia; urine in patients with hemorrhagic cystitis; cerebrospinal fluid in patients with central nervous system involvement; and tissue biopsy in patients with pneumonia, colitis, nephritis, or hepatitis) may be needed to diagnose adenovirus infection. Quantitative PCR of blood is helpful to establish a diagnosis, evaluate risk for dissemination and prognosis, and monitor response to antiviral therapy [<a href="#rid13">13-17,39</a>].</p><p>As has been shown for cytomegalovirus (CMV) infections, early identification of patients at risk for adenovirus disease by monitoring for viremia by PCR is beneficial; thus, some centers have adopted routine weekly surveillance measures for pediatric recipients of allogeneic hematopoietic stem cell transplants [<a href="#rid13">13,40-42</a>]. If viremia is detected, then patients should be carefully evaluated for evidence of disease, such as pneumonia, hepatitis, cystitis, and colitis, and specimens should be obtained for adenovirus testing from affected sites. Although viremia is self-limited in some patients, a rising viral load has been associated with invasive disease [<a href="#rid12">12,13</a>]. In contrast to CMV, the benefit of preemptive treatment based on viremia alone has not been established for adenovirus and is not currently recommended because of the toxicity of the most commonly used antiviral agent, <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a>. Further clinical studies are also needed to identify effective and safe treatments. (See <a class="local">'Treatment'</a> below.)</p><p class="headingAnchor" id="H16"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Most adenovirus infections are self-limited and treatment is supportive. However, adenovirus infections can be fatal in neonates and immunocompromised hosts and rarely in healthy children and adults. Antiviral therapy is generally reserved for patients with severe adenovirus disease, the majority of whom are immunocompromised.</p><p class="headingAnchor" id="H17"><span class="h2">Approach to antiviral therapy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">Cidofovir</a> has been the antiviral agent most frequently used to treat adenovirus infections, but severe nephrotoxicity is a major dose-limiting toxicity. <a class="drug drug_general" data-topicid="131802" href="/d/drug information/131802.html" rel="external">Brincidofovir</a>, an experimental lipid ester of cidofovir that has lower potential for nephrotoxicity than cidofovir, is being studied for adenovirus but is no longer available for use through an <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02596997&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPNjaFgu6oxXJDwzR%2FqaS9WEUqoBPJBm%2B9IKcqgBRz8czQ%3D%3D&amp;TOPIC_ID=8348" target="_blank">expanded access protocol</a> [<a href="#rid43">43</a>].</p><p>Given the potential toxicities of the therapy for adenovirus infections (especially nephrotoxicity with <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a>), an infectious diseases specialist should be consulted when treatment is being considered.</p><p>There have been no controlled trials demonstrating benefit for any antiviral agent in human adenoviral disease.</p><p class="headingAnchor" id="H132387289"><span class="h2">Antiviral agents</span></p><p class="headingAnchor" id="H18"><span class="h3">Cidofovir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">Cidofovir</a> appears more active against adenovirus in vitro than other antiviral drugs such as <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a> [<a href="#rid44">44</a>] and also appears active in vivo as demonstrated by reductions in adenoviral load measured by real-time polymerase chain reaction (PCR) [<a href="#rid14">14,15</a>]. Published data on the efficacy of cidofovir for adenovirus infection in humans are limited to case reports and small nonrandomized studies [<a href="#rid14">14,15,45-49</a>]. In hematopoietic stem cell and lung transplant recipients, cidofovir therapy has been associated with clinical improvement and a suggestion of increased survival [<a href="#rid15">15,45-47</a>].</p><p>Prior to the use of <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a>, the mortality in patients with invasive adenoviral disease following allogeneic hematopoietic cell transplantation (HCT) varied from 25 to 75 percent in different series [<a href="#rid50">50,51</a>], with the higher rates being described in patients with pneumonia and disseminated disease [<a href="#rid15">15,51,52</a>]. In contrast, the mortality rate from adenoviral disease was only 19 percent in a review of 70 published cases of definite or probable adenovirus infection treated with two or more doses of cidofovir; most of these patients were severely immunocompromised (eg, graft-versus-host disease and/or T cell-depleted allografts) [<a href="#rid15">15</a>]. However, in a report of 11 severely immunocompromised patients with adenovirus infection who were treated with cidofovir, five died, including all three with pneumonia [<a href="#rid53">53</a>]. Therefore, although early diagnosis and treatment of adenovirus infections in this patient population may improve outcomes, lymphocyte reconstitution also appears crucial for recovery from disease [<a href="#rid54">54</a>].</p><p>Nephrotoxicity is a major dose-limiting factor for <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a>. As a result, doses of 1 mg/kg every other day or three times per week instead of the standard treatment dose of 5 mg/kg weekly have been used in an attempt to reduce this toxicity [<a href="#rid47">47</a>]. Cidofovir can also cause a Fanconi-type syndrome, with proteinuria, glucosuria, and bicarbonate wasting. When cidofovir is used, it is given together with <a class="drug drug_general" data-topicid="9812" href="/d/drug information/9812.html" rel="external">probenecid</a> and aggressive hydration. Renal function, urine protein, and electrolytes must be monitored closely. Further clinical studies are needed to assess the efficacy and the nephrotoxicity of cidofovir in various dosing schedules. (See  <a class="medical medical_review" href="/d/html/8297.html" rel="external">"Cidofovir: An overview"</a>.)</p><p>Little is known about the appropriate duration of therapy. In patients who tolerate <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a>, it is often continued until resolution of symptomatic disease or viremia. The decision of how long to continue therapy should be made on a case-by-case basis.</p><p class="headingAnchor" id="H5121686"><span class="h3">Brincidofovir</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="131802" href="/d/drug information/131802.html" rel="external">Brincidofovir</a>, an oral lipid ester of <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a>, is an investigational agent that is being studied for the treatment of adenovirus infections [<a href="#rid55">55,56</a>]. This class of agents exhibits enhanced in vitro activity against adenoviruses [<a href="#rid57">57</a>] and has lower potential for nephrotoxicity than cidofovir [<a href="#rid58">58</a>]. Diarrhea has been reported as the most common side effect [<a href="#rid59">59</a>].</p><p>In a report of therapy with <a class="drug drug_general" data-topicid="131802" href="/d/drug information/131802.html" rel="external">brincidofovir</a> in 13 immunocompromised patients (including 11 allogeneic HCT recipients), 9 of 13 demonstrated a virologic response [<a href="#rid55">55</a>]. Patients with a virologic response had longer survival than those without a virologic response (median 196 days versus 55 days).</p><p>In a randomized trial that compared <a class="drug drug_general" data-topicid="131802" href="/d/drug information/131802.html" rel="external">brincidofovir</a> once per week, twice per week, and placebo for asymptomatic adenovirus viremia (&gt;100 copies/mL) in 48 allogeneic HCT recipients with asymptomatic adenovirus viremia (&gt;100 copies/mL), no reduction in treatment failure (disease or rising viremia) was detected with brincidofovir compared with placebo [<a href="#rid56">56</a>]. However, in a post hoc analysis of patients with viremia &gt;1000 copies/mL, significantly more patients assigned to twice weekly brincidofovir than to placebo had undetectable viremia after one week of therapy (8 of 12 versus 2 of 8). There was no evidence of nephrotoxicity or myelotoxicity. However, diarrhea was more common in the treatment group and led to discontinuation in one patient.</p><p>In a retrospective multicenter study of preemptive therapy of adenovirus viremia (&gt;1000 copies/mL) in 27 pediatric allogeneic HCT recipients, virologic responses were observed in 9 percent of patients treated with <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a>, compared with 83 percent treated with <a class="drug drug_general" data-topicid="131802" href="/d/drug information/131802.html" rel="external">brincidofovir</a>, including cidofovir-unresponsive patients [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H19"><span class="h3">Other</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">Ganciclovir</a> has limited activity against adenovirus in vitro [<a href="#rid61">61</a>] and in a hamster model [<a href="#rid62">62</a>]. Neither <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> nor vidarabine has consistent activity against adenovirus in vitro [<a href="#rid63">63</a>]. There are case reports of patients responding to treatment with each of these agents, but the evidence for efficacy in vivo remains anecdotal [<a href="#rid64">64-66</a>].</p><p class="headingAnchor" id="H3212049312"><span class="h2">Monitoring during antiviral therapy</span><span class="headingEndMark"> — </span>When using antivirals, the patient should be monitored with weekly quantitative viral load assessment of blood (if viremic) and respiratory specimens (if the patient has pneumonia) to guide decisions about the duration of therapy. Treatment is usually continued at least until resolution of viremia.</p><p>Patients receiving <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a> require close monitoring for nephrotoxicity and Fanconi-type syndrome. (See <a class="local">'Cidofovir'</a> above.)</p><p class="headingAnchor" id="H20"><span class="h2">Immunotherapy</span><span class="headingEndMark"> — </span>Hypogammaglobulinemia has been associated with severe adenovirus infections [<a href="#rid67">67</a>]. There is some evidence for the use of immunotherapy in the treatment of adenovirus disease in immunocompromised patients. Pooled intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) contains high levels of neutralizing antibodies against common lower adenoviral serotypes [<a href="#rid68">68</a>] and is commonly used as adjunctive therapy in immunocompromised patients [<a href="#rid15">15,38</a>]. In one case, a child with severe combined immunodeficiency (SCID) and a severe adenovirus serotype 7 pneumonia responded rapidly to therapy with high-dose IVIG containing a high titer of neutralizing antibody against serotype 7 [<a href="#rid69">69</a>]. In a murine model of mouse adenovirus infection, passive transfer of adenovirus-specific IgG resulted in a marked delay in mortality [<a href="#rid70">70</a>].</p><p>T cell immunity is critical for recovery from adenovirus infection following hematopoietic stem cell transplantation [<a href="#rid71">71</a>]. Pilot studies of adoptive transfer of T cell immunity have been performed in children with adenovirus infection after stem cell transplantation. In one study, virus-specific donor T cells were isolated and infused into nine children with systemic adenovirus infection [<a href="#rid72">72</a>]. In vivo expansion of adenovirus-specific T cells was demonstrated and viral clearance was attained in five of six evaluable patients. In one patient, adoptive T cell transfer led to exacerbation of preexisting graft-versus-host disease.</p><p>In a study of pediatric HCT recipients treated with donor lymphocytes stimulated in vitro with adenovirus, reductions in viral load were documented in three of three patients with active infection, and clinical improvement was documented in one patient with adenovirus pneumonia [<a href="#rid73">73</a>]. In another study, treatment of two haploidentical HCT recipients who had rising adenovirus loads with donor-derived virus-specific T cells (expanded in vitro using overlapping polypeptides in combination with interleukin-15) resulted in viral clearance in one and reduction of &gt;1.5 log in viral load in the other [<a href="#rid74">74</a>].</p><p>In another study, treatment of adenovirus infections in 17 pediatric stem cell transplant recipients with banked third-party virus-specific T cells (from individuals with common human leukocyte antigen polymorphisms) resulted in complete or partial responses in 78 percent (7 with complete response and 7 with partial response) [<a href="#rid75">75</a>]. There were no significant acute reactions or de novo graft-versus-host disease (GVHD), but several patients had recrudescence of GVHD (in conjunction with steroid taper because of the viral infection).</p><p class="headingAnchor" id="H21"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Vaccination and infection control measures have been applied in certain settings to prevent adenovirus infections.</p><p class="headingAnchor" id="H22"><span class="h2">Vaccination</span><span class="headingEndMark"> — </span>Live oral enteric-coated vaccines directed against adenovirus serotypes 4 and 7 had been used for years in military recruits [<a href="#rid76">76</a>]. They are safe and effective in the prevention of epidemics of acute respiratory disease in military training camps. In the 1990s, the manufacturer of the vaccines stopped production. Subsequently, new outbreaks of adenovirus serotypes 4 and 7 disease in training camps occurred, including several fatalities, underscoring the continued need for the vaccine [<a href="#rid77">77-79</a>]. In addition, adenovirus serotype 14, a subtype B2 adenovirus, emerged in military recruit training sites and became the predominant strain. (See  <a class="medical medical_review" href="/d/html/8339.html" rel="external">"Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection", section on 'Adenovirus serotype 14'</a>.)</p><p>In 2011, a new live, oral <a class="drug drug_general" data-topicid="16483" href="/d/drug information/16483.html" rel="external">adenovirus vaccine</a> against adenovirus serotypes 4 and 7 was approved for use in United States military personnel aged 17 through 50 years [<a href="#rid80">80,81</a>]. During the two years following reintroduction of the vaccine, United States military trainees had a 100-fold decline in adenovirus disease burden (from 5.8 to 0.02 cases per 1000 person-weeks) [<a href="#rid82">82</a>]. There was also a marked decline in the incidence of disease caused by adenovirus serotypes other than 4 and 7, including adenovirus serotype 14. These data suggest that the emergence of adenovirus 14 in military recruits during the non-vaccination period was related to the discontinuation of the adenovirus serotypes 4 and 7 vaccine program, since heterotypic antibodies to adenovirus 14 develop following adenovirus 7 immunization [<a href="#rid79">79,83,84</a>]. (See  <a class="medical medical_review" href="/d/html/8339.html" rel="external">"Pathogenesis, epidemiology, and clinical manifestations of adenovirus infection", section on 'Adenovirus serotype 14'</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Infection control</span><span class="headingEndMark"> — </span>Adenoviruses can stay viable for prolonged periods on environmental surfaces such as sinks and hand towels, and they are not susceptible to some commonly used disinfectants such as alcohol and ether [<a href="#rid85">85</a>]. Therefore, decontamination of environmental surfaces and instruments may be difficult and requires specific agents such as chlorine, formaldehyde, or heat. Outbreaks of pharyngoconjunctival fever from swimming pool exposure have usually been associated with inadequate water chlorination [<a href="#rid86">86</a>].</p><p>Adenoviruses can cause significant healthcare-associated infections [<a href="#rid87">87-89</a>]. In one report, 126 (7 percent) of 1870 ophthalmology clinic patients developed epidemic keratoconjunctivitis (EKC) due to adenovirus serotype 8 [<a href="#rid87">87</a>]. Transmission was attributed to inadequate disinfection of instruments and to finger-to-eye transmission by healthcare workers. Of note, hand washing did not reliably remove adenoviruses from contaminated fingers. The recommendations from this study included using gloves to examine patients with EKC and decontaminating instruments with 10% bleach. In another study, contamination of multidose dilating eye drop vials was implicated in an outbreak at a large, hospital-affiliated eye clinic that affected 44 patients [<a href="#rid90">90</a>].</p><p>In another report, an epidemic of adenovirus serotype 7 occurred in a neonatal intensive care nursery resulting in the death of two patients [<a href="#rid88">88</a>]. Symptomatic infection occurred in 9 patients, 10 staff, and 3 parents. The outbreak was controlled by cohorting patients, using gloves, gowns, and goggles, and excluding symptomatic staff from the unit.</p><p>Prolonged infection control measures may be necessary to ensure elimination of adenovirus following a healthcare-associated outbreak [<a href="#rid91">91</a>]. The Committee on Infectious Diseases of the American Academy of Pediatrics recommends the following [<a href="#rid92">92</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with conjunctivitis and for patients with gastroenteritis who are incontinent or in diapers, contact precautions should be maintained for the duration of the illness. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Contact precautions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those with respiratory tract infections, contact and droplet precautions are recommended for the duration of the hospitalization. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Droplet precautions'</a> and  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Contact precautions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disposable gloves and assiduous hand washing should be used when caring for infected patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Healthcare personnel with known or suspected adenoviral conjunctivitis should avoid direct patient contact until symptoms have resolved.</p><p></p><p>Children who participate in group childcare, particularly during the first two years of life, are at increased risk for adenoviral respiratory tract infections and gastroenteritis. Specific preventive measures in this setting have not been established.</p><p class="headingAnchor" id="H105830399"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83054.html" rel="external">"Patient education: Adenovirus infections (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H12480845"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical criteria are not sufficient to accurately diagnose adenovirus infection. Laboratory confirmation of adenovirus infection should be performed if there is suspicion of this diagnosis and confirmation would be helpful in making decisions about antiviral therapy, excluding other treatable infections, establishing a prognosis, and continuing infection control measures when appropriate. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnostic tests for adenovirus include viral culture, viral antigen assays (adenovirus-specific enzyme-linked immunosorbent assay or immunofluorescence assay), polymerase chain reaction assays, histopathologic studies, and serology (<a class="graphic graphic_table graphicRef59727" href="/d/graphic/59727.html" rel="external">table 1</a>). (See <a class="local">'Diagnostic tests'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnostic test of choice varies depending upon the clinical scenario (<a class="graphic graphic_table graphicRef81573" href="/d/graphic/81573.html" rel="external">table 3</a>). (See <a class="local">'Diagnostic tests of choice for different adenovirus syndromes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most adenovirus infections are self-limited and treatment is supportive. Antiviral therapy generally is reserved for immunocompromised hosts and patients with severe disease, but controlled clinical trials have not been performed. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When treatment is indicated, <a class="drug drug_general" data-topicid="9264" href="/d/drug information/9264.html" rel="external">cidofovir</a> has been the antiviral agent most frequently used. Nephrotoxicity is a major dose-limiting factor for cidofovir. <a class="drug drug_general" data-topicid="131802" href="/d/drug information/131802.html" rel="external">Brincidofovir</a>, an experimental oral lipid ester of cidofovir that has lower potential for nephrotoxicity than cidofovir, has enhanced in vitro activity against adenoviruses but is not available for compassionate use. An infectious diseases specialist should be consulted when treatment is being considered. (See <a class="local">'Approach to antiviral therapy'</a> above and <a class="local">'Cidofovir'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pooled intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> has been used as adjunctive therapy in immunocompromised patients, but controlled clinical trials have not been reported. Adoptive transfer of donor or third-party adenovirus-specific T cells appear promising for treatment of adenovirus infections in stem cell transplant recipients. (See <a class="local">'Immunotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of adenovirus transmission requires decontamination of environmental surfaces and instruments with agents such as chlorine, formaldehyde, or heat; adenoviruses are not susceptible to alcohol, ether, or many other commonly used disinfectants. (See <a class="local">'Infection control'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hospitalized patients with gastrointestinal, conjunctival, and respiratory adenovirus infection should be placed on contact precautions; those with respiratory infection should also be placed on droplet precautions. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Droplet precautions'</a> and  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Contact precautions'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fox JP, Hall CE, Cooney MK. The Seattle Virus Watch. VII. Observations of adenovirus infections. Am J Epidemiol 1977; 105:362.</a></li><li><a class="nounderline abstract_t">Edwards KM, Thompson J, Paolini J, Wright PF. Adenovirus infections in young children. Pediatrics 1985; 76:420.</a></li><li><a class="nounderline abstract_t">Munoz FM, Piedra PA, Demmler GJ. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis 1998; 27:1194.</a></li><li><a class="nounderline abstract_t">Basu G, Rossouw J, Sebunya TK, et al. Prevalence of rotavirus, adenovirus and astrovirus infection in young children with gastroenteritis in Gaborone, Botswana. East Afr Med J 2003; 80:652.</a></li><li><a class="nounderline abstract_t">Levent F, Greer JM, Snider M, Demmler-Harrison GJ. Performance of a new immunochromatographic assay for detection of adenoviruses in children. J Clin Virol 2009; 44:173.</a></li><li><a class="nounderline abstract_t">Raboni SM, Siqueira MM, Portes SR, Pasquini R. Comparison of PCR, enzyme immunoassay and conventional culture for adenovirus detection in bone marrow transplant patients with hemorrhagic cystitis. J Clin Virol 2003; 27:270.</a></li><li><a class="nounderline abstract_t">Herrmann JE, Perron-Henry DM, Blacklow NR. Antigen detection with monoclonal antibodies for the diagnosis of adenovirus gastroenteritis. J Infect Dis 1987; 155:1167.</a></li><li><a class="nounderline abstract_t">Allard A, Albinsson B, Wadell G. Detection of adenoviruses in stools from healthy persons and patients with diarrhea by two-step polymerase chain reaction. J Med Virol 1992; 37:149.</a></li><li><a class="nounderline abstract_t">Claas EC, Schilham MW, de Brouwer CS, et al. Internally controlled real-time PCR monitoring of adenovirus DNA load in serum or plasma of transplant recipients. J Clin Microbiol 2005; 43:1738.</a></li><li><a class="nounderline abstract_t">Damen M, Minnaar R, Glasius P, et al. Real-time PCR with an internal control for detection of all known human adenovirus serotypes. J Clin Microbiol 2008; 46:3997.</a></li><li><a class="nounderline abstract_t">Heim A, Ebnet C, Harste G, Pring-Akerblom P. Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J Med Virol 2003; 70:228.</a></li><li><a class="nounderline abstract_t">Echavarria M, Forman M, van Tol MJ, et al. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet 2001; 358:384.</a></li><li><a class="nounderline abstract_t">Lion T, Baumgartinger R, Watzinger F, et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 2003; 102:1114.</a></li><li><a class="nounderline abstract_t">Leruez-Ville M, Minard V, Lacaille F, et al. Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection. Clin Infect Dis 2004; 38:45.</a></li><li><a class="nounderline abstract_t">Neofytos D, Ojha A, Mookerjee B, et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 2007; 13:74.</a></li><li><a class="nounderline abstract_t">Lankester AC, Heemskerk B, Claas EC, et al. Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection. Clin Infect Dis 2004; 38:1521.</a></li><li><a class="nounderline abstract_t">Lankester AC, van Tol MJ, Claas EC, et al. Quantification of adenovirus DNA in plasma for management of infection in stem cell graft recipients. Clin Infect Dis 2002; 34:864.</a></li><li><a class="nounderline abstract_t">Gray GC, McCarthy T, Lebeck MG, et al. Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004-2006. Clin Infect Dis 2007; 45:1120.</a></li><li><a class="nounderline abstract_t">Martin AB, Webber S, Fricker FJ, et al. Acute myocarditis. Rapid diagnosis by PCR in children. Circulation 1994; 90:330.</a></li><li><a class="nounderline abstract_t">Towbin JA, Griffin LD, Martin AB, et al. Intrauterine adenoviral myocarditis presenting as nonimmune hydrops fetalis: diagnosis by polymerase chain reaction. Pediatr Infect Dis J 1994; 13:144.</a></li><li><a class="nounderline abstract_t">Shirali GS, Ni J, Chinnock RE, et al. Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med 2001; 344:1498.</a></li><li><a class="nounderline abstract_t">Becroft DM. Histopathology of fatal adenovirus infection of the respiratory tract in young children. J Clin Pathol 1967; 20:561.</a></li><li><a class="nounderline abstract_t">Landry ML, Fong CK, Neddermann K, et al. Disseminated adenovirus infection in an immunocompromised host. Pitfalls in diagnosis. Am J Med 1987; 83:555.</a></li><li><a class="nounderline abstract_t">Pinkerton H, Carroll S. Fatal adenovirus pneumonia in infants. Correlation of histologic and electron microscopic observations. Am J Pathol 1971; 65:543.</a></li><li><a class="nounderline abstract_t">Matsuoka T, Naito T, Kubota Y, et al. Disseminated adenovirus (type 19) infection in a neonate. Rapid detection of the infection by immunofluorescence. Acta Paediatr Scand 1990; 79:568.</a></li><li><a class="nounderline abstract_t">Wu TC, Kanayama MD, Hruban RH, et al. Virus-associated RNAs (VA-I and VA-II). An efficient target for the detection of adenovirus infections by in situ hybridization. Am J Pathol 1992; 140:991.</a></li><li class="breakAll">Horwitz MS. Adenoviruses. In: Fields Virology, 3rd ed, Fields BN, Knipe DM, Howley PM (Eds), Lippincott-Raven Publishers, Philadelphia 1996. p.2160.</li><li><a class="nounderline abstract_t">McMinn PC, Stewart J, Burrell CJ. A community outbreak of epidemic keratoconjunctivitis in central Australia due to adenovirus type 8. J Infect Dis 1991; 164:1113.</a></li><li class="breakAll">National Institute for Health and Care Excellence. AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis. Medtech innovation briefing [MIB46]. December 2015. Available at: https://www.nice.org.uk/advice/mib46/chapter/introduction (Accessed on April 19, 2018).</li><li><a class="nounderline abstract_t">Sambursky R, Trattler W, Tauber S, et al. Sensitivity and specificity of the AdenoPlus test for diagnosing adenoviral conjunctivitis. JAMA Ophthalmol 2013; 131:17.</a></li><li><a class="nounderline abstract_t">Kam KY, Ong HS, Bunce C, et al. Sensitivity and specificity of the AdenoPlus point-of-care system in detecting adenovirus in conjunctivitis patients at an ophthalmic emergency department: a diagnostic accuracy study. Br J Ophthalmol 2015; 99:1186.</a></li><li><a class="nounderline abstract_t">Klinger JR, Sanchez MP, Curtin LA, et al. Multiple cases of life-threatening adenovirus pneumonia in a mental health care center. Am J Respir Crit Care Med 1998; 157:645.</a></li><li><a class="nounderline abstract_t">Yang E, Rubin BK. "Childhood" viruses as a cause of pneumonia in adults. Semin Respir Infect 1995; 10:232.</a></li><li><a class="nounderline abstract_t">Lee WM, Grindle K, Pappas T, et al. High-throughput, sensitive, and accurate multiplex PCR-microsphere flow cytometry system for large-scale comprehensive detection of respiratory viruses. J Clin Microbiol 2007; 45:2626.</a></li><li><a class="nounderline abstract_t">Caliendo AM. Multiplex PCR and emerging technologies for the detection of respiratory pathogens. Clin Infect Dis 2011; 52 Suppl 4:S326.</a></li><li><a class="nounderline abstract_t">Self WH, Williams DJ, Zhu Y, et al. Respiratory Viral Detection in Children and Adults: Comparing Asymptomatic Controls and Patients With Community-Acquired Pneumonia. J Infect Dis 2016; 213:584.</a></li><li><a class="nounderline abstract_t">Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002; 100:1619.</a></li><li><a class="nounderline abstract_t">Myers GD, Bollard CM, Wu MF, et al. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39:677.</a></li><li><a class="nounderline abstract_t">Erard V, Huang ML, Ferrenberg J, et al. Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease. Clin Infect Dis 2007; 45:958.</a></li><li><a class="nounderline abstract_t">Yusuf U, Hale GA, Carr J, et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation 2006; 81:1398.</a></li><li><a class="nounderline abstract_t">Sivaprakasam P, Carr TF, Coussons M, et al. Improved outcome from invasive adenovirus infection in pediatric patients after hemopoietic stem cell transplantation using intensive clinical surveillance and early intervention. J Pediatr Hematol Oncol 2007; 29:81.</a></li><li><a class="nounderline abstract_t">Watson T, MacDonald D, Song X, et al. Risk factors for molecular detection of adenovirus in pediatric hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2012; 18:1227.</a></li><li class="breakAll">ClinicalTrials.gov. Expanded access protocol to provide brincidofovir for the treatment of serious adenovirus infection or disease. https://clinicaltrials.gov/ct2/show/NCT02596997 (Accessed on April 26, 2018).</li><li><a class="nounderline abstract_t">Kodama E, Shigeta S, Suzuki T, De Clercq E. Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method. Antiviral Res 1996; 31:159.</a></li><li><a class="nounderline abstract_t">Legrand F, Berrebi D, Houhou N, et al. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant 2001; 27:621.</a></li><li><a class="nounderline abstract_t">Ljungman P, Ribaud P, Eyrich M, et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003; 31:481.</a></li><li><a class="nounderline abstract_t">Doan ML, Mallory GB, Kaplan SL, et al. Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients. J Heart Lung Transplant 2007; 26:883.</a></li><li><a class="nounderline abstract_t">Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7:388.</a></li><li><a class="nounderline abstract_t">Alcamo AM, Wolf MS, Alessi LJ, et al. Successful Use of Cidofovir in an Immunocompetent Child With Severe Adenoviral Sepsis. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994; 169:775.</a></li><li><a class="nounderline abstract_t">La Rosa AM, Champlin RE, Mirza N, et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001; 32:871.</a></li><li><a class="nounderline abstract_t">Baldwin A, Kingman H, Darville M, et al. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant 2000; 26:1333.</a></li><li><a class="nounderline abstract_t">Symeonidis N, Jakubowski A, Pierre-Louis S, et al. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. Transpl Infect Dis 2007; 9:108.</a></li><li><a class="nounderline abstract_t">Heemskerk B, Lankester AC, van Vreeswijk T, et al. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J Infect Dis 2005; 191:520.</a></li><li><a class="nounderline abstract_t">Florescu DF, Pergam SA, Neely MN, et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant 2012; 18:731.</a></li><li><a class="nounderline abstract_t">Grimley MS, Chemaly RF, Englund JA, et al. Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial. Biol Blood Marrow Transplant 2017; 23:512.</a></li><li><a class="nounderline abstract_t">Hartline CB, Gustin KM, Wan WB, et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis 2005; 191:396.</a></li><li><a class="nounderline abstract_t">Ciesla SL, Trahan J, Wan WB, et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 2003; 59:163.</a></li><li><a class="nounderline abstract_t">Marty FM, Winston DJ, Chemaly RF, et al. Brincidofovir for prevention of cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT) in CMV-seropositive patients: a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial. Biol Blood Marrow Transplant 2016; 22:S23.</a></li><li><a class="nounderline abstract_t">Hiwarkar P, Amrolia P, Sivaprakasam P, et al. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood 2017; 129:2033.</a></li><li><a class="nounderline abstract_t">Taylor DL, Jeffries DJ, Taylor-Robinson D, et al. The susceptibility of adenovirus infection to the anti-cytomegalovirus drug, ganciclovir (DHPG). FEMS Microbiol Lett 1988; 49:337.</a></li><li><a class="nounderline abstract_t">Ying B, Tollefson AE, Spencer JF, et al. Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters. Antimicrob Agents Chemother 2014; 58:7171.</a></li><li><a class="nounderline abstract_t">Baba M, Mori S, Shigeta S, De Clercq E. Selective inhibitory effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 2'-nor-cyclic GMP on adenovirus replication in vitro. Antimicrob Agents Chemother 1987; 31:337.</a></li><li><a class="nounderline abstract_t">Sabroe I, McHale J, Tait DR, et al. Treatment of adenoviral pneumonitis with intravenous ribavirin and immunoglobulin. Thorax 1995; 50:1219.</a></li><li><a class="nounderline abstract_t">Hromas R, Clark C, Blanke C, et al. Failure of ribavirin to clear adenovirus infections in T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14:663.</a></li><li><a class="nounderline abstract_t">Kawakami M, Ueda S, Maeda T, et al. Vidarabine therapy for virus-associated cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 20:485.</a></li><li><a class="nounderline abstract_t">Mawhorter S, Yamani MH. Hypogammaglobulinemia and infection risk in solid organ transplant recipients. Curr Opin Organ Transplant 2008; 13:581.</a></li><li><a class="nounderline abstract_t">Flomenberg PR, Chen M, Munk G, Horwitz MS. Molecular epidemiology of adenovirus type 35 infections in immunocompromised hosts. J Infect Dis 1987; 155:1127.</a></li><li><a class="nounderline abstract_t">Dagan R, Schwartz RH, Insel RA, Menegus MA. Severe diffuse adenovirus 7a pneumonia in a child with combined immunodeficiency: possible therapeutic effect of human immune serum globulin containing specific neutralizing antibody. Pediatr Infect Dis 1984; 3:246.</a></li><li><a class="nounderline abstract_t">Lenaerts L, Kelchtermans H, Geboes L, et al. Recovery of humoral immunity is critical for successful antiviral therapy in disseminated mouse adenovirus type 1 infection. Antimicrob Agents Chemother 2008; 52:1462.</a></li><li><a class="nounderline abstract_t">Hromas R, Cornetta K, Srour E, et al. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood 1994; 84:1689.</a></li><li><a class="nounderline abstract_t">Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134:64.</a></li><li><a class="nounderline abstract_t">Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12:1160.</a></li><li><a class="nounderline abstract_t">Geyeregger R, Freimüller C, Stemberger J, et al. First-in-man clinical results with good manufacturing practice (GMP)-compliant polypeptide-expanded adenovirus-specific T cells after haploidentical hematopoietic stem cell transplantation. J Immunother 2014; 37:245.</a></li><li><a class="nounderline abstract_t">Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013; 121:5113.</a></li><li><a class="nounderline abstract_t">Top FH Jr, Dudding BA, Russell PK, Buescher EL. Control of respiratory disease in recruits with types 4 and 7 adenovirus vaccines. Am J Epidemiol 1971; 94:142.</a></li><li><a class="nounderline abstract_t">Barraza EM, Ludwig SL, Gaydos JC, Brundage JF. Reemergence of adenovirus type 4 acute respiratory disease in military trainees: report of an outbreak during a lapse in vaccination. J Infect Dis 1999; 179:1531.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Two fatal cases of adenovirus-related illness in previously healthy young adults--Illinois, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:553.</a></li><li><a class="nounderline abstract_t">Metzgar D, Osuna M, Kajon AE, et al. Abrupt emergence of diverse species B adenoviruses at US military recruit training centers. J Infect Dis 2007; 196:1465.</a></li><li><a class="nounderline abstract_t">Lyons A, Longfield J, Kuschner R, et al. A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine 2008; 26:2890.</a></li><li class="breakAll">Adenovirus type 4 and type 7 live oral vaccine prescribing information. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM247515.pdf (Accessed on March 03, 2021).</li><li><a class="nounderline abstract_t">Radin JM, Hawksworth AW, Blair PJ, et al. Dramatic decline of respiratory illness among US military recruits after the renewed use of adenovirus vaccines. Clin Infect Dis 2014; 59:962.</a></li><li><a class="nounderline abstract_t">Binn LN, Sanchez JL, Gaydos JC. Emergence of adenovirus type 14 in US military recruits--a new challenge. J Infect Dis 2007; 196:1436.</a></li><li><a class="nounderline abstract_t">van der VEEN, PRINS A. Studies of the significance of the recall phenomenon in the antibody response to adenovirus vaccine and infection. J Immunol 1960; 84:562.</a></li><li><a class="nounderline abstract_t">Buehler JW, Finton RJ, Goodman RA, et al. Epidemic keratoconjunctivitis: report of an outbreak in an ophthalmology practice and recommendations for prevention. Infect Control 1984; 5:390.</a></li><li><a class="nounderline abstract_t">D'Angelo LJ, Hierholzer JC, Keenlyside RA, et al. Pharyngoconjunctival fever caused by adenovirus type 4: report of a swimming pool-related outbreak with recovery of virus from pool water. J Infect Dis 1979; 140:42.</a></li><li><a class="nounderline abstract_t">Jernigan JA, Lowry BS, Hayden FG, et al. Adenovirus type 8 epidemic keratoconjunctivitis in an eye clinic: risk factors and control. J Infect Dis 1993; 167:1307.</a></li><li><a class="nounderline abstract_t">Finn A, Anday E, Talbot GH. An epidemic of adenovirus 7a infection in a neonatal nursery: course, morbidity, and management. Infect Control Hosp Epidemiol 1988; 9:398.</a></li><li><a class="nounderline abstract_t">Faden H, Wynn RJ, Campagna L, Ryan RM. Outbreak of adenovirus type 30 in a neonatal intensive care unit. J Pediatr 2005; 146:523.</a></li><li><a class="nounderline abstract_t">Muller MP, Siddiqui N, Ivancic R, Wong D. Adenovirus-related epidemic keratoconjunctivitis outbreak at a hospital-affiliated ophthalmology clinic. Am J Infect Control 2018; 46:581.</a></li><li><a class="nounderline abstract_t">Piedra PA. Adenovirus in the neonatal intensive care unit: formidable, forgotten foe. J Pediatr 2005; 146:447.</a></li><li class="breakAll">American Academy of Pediatrics. Adenovirus infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.188.</li></ol></div><div id="topicVersionRevision">Topic 8348 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/192073" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The Seattle Virus Watch. VII. Observations of adenovirus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2993992" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Adenovirus infections in young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9827268" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Disseminated adenovirus disease in immunocompromised and immunocompetent children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15018423" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence of rotavirus, adenovirus and astrovirus infection in young children with gastroenteritis in Gaborone, Botswana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19101199" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Performance of a new immunochromatographic assay for detection of adenoviruses in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12878091" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Comparison of PCR, enzyme immunoassay and conventional culture for adenovirus detection in bone marrow transplant patients with hemorrhagic cystitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3033091" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antigen detection with monoclonal antibodies for the diagnosis of adenovirus gastroenteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1629713" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Detection of adenoviruses in stools from healthy persons and patients with diarrhea by two-step polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15814994" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Internally controlled real-time PCR monitoring of adenovirus DNA load in serum or plasma of transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18923006" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Real-time PCR with an internal control for detection of all known human adenovirus serotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12696109" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Rapid and quantitative detection of human adenovirus DNA by real-time PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11502321" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prediction of severe disseminated adenovirus infection by serum PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12702513" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14679447" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222755" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of adenovirus disease in stem cell transplant recipients with cidofovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15156436" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11850866" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Quantification of adenovirus DNA in plasma for management of infection in stem cell graft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17918073" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8026015" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Acute myocarditis. Rapid diagnosis by PCR in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8190541" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Intrauterine adenoviral myocarditis presenting as nonimmune hydrops fetalis: diagnosis by polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11357152" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Association of viral genome with graft loss in children after cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4301496" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Histopathology of fatal adenovirus infection of the respiratory tract in young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2821806" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Disseminated adenovirus infection in an immunocompromised host. Pitfalls in diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4330417" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Fatal adenovirus pneumonia in infants. Correlation of histologic and electron microscopic observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2166992" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Disseminated adenovirus (type 19) infection in a neonate. Rapid detection of the infection by immunofluorescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1314030" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Virus-associated RNAs (VA-I and VA-II). An efficient target for the detection of adenovirus infections by in situ hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1314030" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Virus-associated RNAs (VA-I and VA-II). An efficient target for the detection of adenovirus infections by in situ hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1955711" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A community outbreak of epidemic keratoconjunctivitis in central Australia due to adenovirus type 8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1955711" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A community outbreak of epidemic keratoconjunctivitis in central Australia due to adenovirus type 8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23307204" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Sensitivity and specificity of the AdenoPlus test for diagnosing adenoviral conjunctivitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25824258" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sensitivity and specificity of the AdenoPlus point-of-care system in detecting adenovirus in conjunctivitis patients at an ophthalmic emergency department: a diagnostic accuracy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9476884" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Multiple cases of life-threatening adenovirus pneumonia in a mental health care center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8668851" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : "Childhood" viruses as a cause of pneumonia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17537928" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : High-throughput, sensitive, and accurate multiplex PCR-microsphere flow cytometry system for large-scale comprehensive detection of respiratory viruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460291" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Multiplex PCR and emerging technologies for the detection of respiratory pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26180044" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Respiratory Viral Detection in Children and Adults: Comparing Asymptomatic Controls and Patients With Community-Acquired Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12176880" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17417664" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17879908" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16732176" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17279003" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Improved outcome from invasive adenovirus infection in pediatric patients after hemopoietic stem cell transplantation using intensive clinical surveillance and early intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22281300" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Risk factors for molecular detection of adenovirus in pediatric hematopoietic stem cell transplantation recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22281300" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Risk factors for molecular detection of adenovirus in pediatric hematopoietic stem cell transplantation recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8811200" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11319592" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12665844" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17845926" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11529489" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31826930" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Successful Use of Cidofovir in an Immunocompetent Child With Severe Adenoviral Sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8133091" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Increasing incidence of adenovirus disease in bone marrow transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11247710" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Adenovirus infections in adult recipients of blood and marrow transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11223974" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17461995" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15655775" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21963623" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28063938" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15633099" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12927306" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Brincidofovir for prevention of cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT) in CMV-seropositive patients: a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28153824" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The susceptibility of adenovirus infection to the anti-cytomegalovirus drug, ganciclovir (DHPG)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25224011" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3566256" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Selective inhibitory effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 2'-nor-cyclic GMP on adenovirus replication in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8553282" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment of adenoviral pneumonitis with intravenous ribavirin and immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7858548" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Failure of ribavirin to clear adenovirus infections in T cell-depleted allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9313882" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Vidarabine therapy for virus-associated cystitis after allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19060546" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hypogammaglobulinemia and infection risk in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3033089" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Molecular epidemiology of adenovirus type 35 infections in immunocompromised hosts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6330708" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Severe diffuse adenovirus 7a pneumonia in a child with combined immunodeficiency: possible therapeutic effect of human immune serum globulin containing specific neutralizing antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18268085" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Recovery of humoral immunity is critical for successful antiviral therapy in disseminated mouse adenovirus type 1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8068960" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16803570" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16998485" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24714358" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : First-in-man clinical results with good manufacturing practice (GMP)-compliant polypeptide-expanded adenovirus-specific T cells after haploidentical hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23610374" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4327997" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Control of respiratory disease in recruits with types 4 and 7 adenovirus vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228076" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Reemergence of adenovirus type 4 acute respiratory disease in military trainees: report of an outbreak during a lapse in vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11456329" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Two fatal cases of adenovirus-related illness in previously healthy young adults--Illinois, 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18008225" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Abrupt emergence of diverse species B adenoviruses at US military recruit training centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18448211" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18448211" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24991024" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Dramatic decline of respiratory illness among US military recruits after the renewed use of adenovirus vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18008220" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Emergence of adenovirus type 14 in US military recruits--a new challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13841541" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Studies of the significance of the recall phenomenon in the antibody response to adenovirus vaccine and infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6090333" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Epidemic keratoconjunctivitis: report of an outbreak in an ophthalmology practice and recommendations for prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/222852" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pharyngoconjunctival fever caused by adenovirus type 4: report of a swimming pool-related outbreak with recovery of virus from pool water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8501319" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Adenovirus type 8 epidemic keratoconjunctivitis in an eye clinic: risk factors and control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2844886" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : An epidemic of adenovirus 7a infection in a neonatal nursery: course, morbidity, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15812457" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Outbreak of adenovirus type 30 in a neonatal intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29305276" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Adenovirus-related epidemic keratoconjunctivitis outbreak at a hospital-affiliated ophthalmology clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15812443" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Adenovirus in the neonatal intensive care unit: formidable, forgotten foe.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
